Acadia Pharmaceuticals (ACAD) grants CEO large options and RSUs

Rhea-AI Filing Summary

ACADIA PHARMACEUTICALS INC reported that Chief Executive Officer Owen Adams Catherine received new equity awards. She was granted stock options for 263,005 shares of common stock at an exercise price of 22.1600, vesting 25% on March 6, 2027, with the remainder vesting in 36 equal monthly installments and expiring on March 5, 2036. She also received 76,509 restricted stock units, each representing one share of common stock, vesting in four equal annual installments beginning March 6, 2027. These awards are compensation grants and do not involve any open-market purchases or sales.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Owen Adams Catherine

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	263,005	$0.00	--
Grant/Award	Restricted Stock Units	76,509	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 263,005 shares (Direct); Restricted Stock Units — 76,509 shares (Direct)

Footnotes (1)

1. 25% of the shares subject to the Stock Option will vest and become exercisable on March 6, 2027. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. The restricted stock units vest in four equal annual installments beginning March 6, 2027.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Owen Adams Catherine

(Last) (First) (Middle)

C/O ACADIA PHARMACEUTICALS INC.

12830 EL CAMINO REAL, SUITE 400

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ACADIA PHARMACEUTICALS INC [ ACAD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$22.16	03/06/2026		A		263,005		(1)	03/05/2036	Common Stock	263,005	$0	263,005	D
Restricted Stock Units	(2)	03/06/2026		A		76,509		(3)	(3)	Common Stock	76,509	$0	76,509	D

Explanation of Responses:

1. 25% of the shares subject to the Stock Option will vest and become exercisable on March 6, 2027. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.

2. Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.

3. The restricted stock units vest in four equal annual installments beginning March 6, 2027.

	/s/ Jennifer J. Rhodes, Attorney-in-Fact	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did ACAD CEO Owen Adams Catherine report in the latest Form 4?

The Form 4 shows Owen Adams Catherine received compensation grants of stock options and restricted stock units, increasing her equity-based incentives without any open-market buying or selling of ACAD common shares disclosed in this filing.

How many stock options were granted to the ACAD CEO and at what exercise price?

Owen Adams Catherine was granted 263,005 stock options, each allowing her to buy one share of ACAD common stock at an exercise price of 22.1600 per share, subject to a long-term vesting schedule beginning in 2027.

What is the vesting schedule for the new ACAD stock option grant to the CEO?

For the stock options, 25% of the 263,005 shares vest and become exercisable on March 6, 2027. The remaining 75% then vest in 36 equal monthly installments, providing a multi-year retention and performance incentive structure for the CEO.

How many restricted stock units did ACAD grant to its CEO and how do they work?

ACAD granted 76,509 restricted stock units to Owen Adams Catherine. Each restricted stock unit represents a contingent right to receive one share of common stock, giving her future ownership if vesting conditions are satisfied over time.

When do the ACAD CEO’s restricted stock units begin vesting?

The 76,509 restricted stock units vest in four equal annual installments starting March 6, 2027. This means one quarter of the units convert into common shares each year from that date, aligning her compensation with longer-term company performance.

Does the ACAD Form 4 show any stock purchases or sales by the CEO?

The filing reports only grant-type acquisitions of stock options and restricted stock units for the CEO. It does not show any open-market purchases or sales of ACAD common stock, indicating these are compensation-related awards rather than trading activity.